神経変性疾患における標的型タンパク質分解の現在の傾向
Gulshan Kumar1, Vaibhav Thakur2, Satish Sardana1
1Amity Institute of Pharmacy, Amity University Haryana, 122413, India.
European journal of medicinal chemistry
|September 6, 2025
まとめ
標的型タンパク質分解 (TPD) は,有害な誤折りたたまれたタンパク質をクリアすることで,神経変性疾患 (ND) の治療の新たな方法を提供します. PROTACやLYTACのような新型TPD技術は,NDSにおける薬剤発見に有望です.
科学分野:
- 神経科学
- 分子生物学
- 薬物の発見
背景:
- 神経変性疾患 (ND) は,誤ったタンパク質の蓄積 (例えば,アミロイドベータ,タウ,アルファシヌクレイン) による認知および運動能力の低下を伴う.
- 伝統的な小分子薬は これらの病気を引き起こすタンパク質を 効果的に標的とするのに苦労します
研究 の 目的:
- 新興の標的型タンパク質分解 (TPD) 技術の概要を提示する.
- 神経変性疾患の治療におけるTPDの潜在的応用を探求する.
- TPDの急速に進歩する分野の研究者を導くために.
主な方法:
- タンパク質分解標的キメラ (PROTACs) とライソソーム標的キメラ (LYTACs) のレビュー
- 分子接着剤,抗体ベースの PROTACs (AbTACs),および AUTOphagy-TTargeting Chimeras (AUTOTACs) を含む新しい TPD 戦略についての議論.
- 細胞破壊経路を活用する TPD のメカニズムの分析
主要な成果:
- PROTACsとLYTACsを含むTPD戦略は,疾患に関連したタンパク質を排除する重要な可能性を実証しています.
- 新興のTPD技術は NDの治療の可能性を拡大しています
- これらの方法は,以前は薬効性のないタンパク質をターゲットにすることで,薬剤発見のための新しい道を開きます.
結論:
- 標的型タンパク質分解は 神経変性疾患の有望な治療戦略です
- TPD技術の進歩は アルツハイマー病や パーキンソン病や ハンチントン病などの 新規治療法の開発に不可欠です
- このレビューは,生物学者や化学者のためのTPDの発展のガイドとして機能します.
関連する概念動画
Regulated Protein Degradation
7.6K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.6K
The Proteasome
1.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.1K
Protein Networks
4.1K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.1K
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Proteins: From Genes to Degradation
3.6K
3.6K
Amyloid Fibrils
9.8K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.8K


